I-BFM Initiative on CSF ALL Biomarkers is an international collaboration of research groups, working on advancing the research field of paediatric central nervous system (CNS) involvement of acute lymphoblastic leukaemia (ALL).<\/p>\n
The very first meeting of physicians and researchers interested in the field was initiated by Prof. Christina Halsey in 2018 at the annual I-BFM conference in Helsinki. The initiative\u2019s online meetings to tackle operative targets has been organised by D\u00e1niel Erd\u00e9lyi since November 2020.<\/p>\n
Participating work groups:<\/p>\n
ALL is the most common malignant disease in children. In the last two decades, highly sensitive methods were developed to monitor minimal residual disease in the bone marrow (BM). These led to restructured treatment regimens, and consequently improved survival rates vastly. Patients who develop central nervous system (CNS) involvement, however, face inferior prognosis. Diagnostic methods of the cerebrospinal fluid (CSF) underperform compared to those of the BM. The current standards are all based on cell-detection methods in the CSF (automated or manual cell counting, light microscopy evaluation of cytocentrifuge smears, flow cytometry) acquired via lumbar puncture. These conventional methods were found to provide high rate (>40%) of false negative results among patients with proven CNS-involvement as per neuro imaging or autopsy. In fact, majority of tumour cells adhere to the meninges or specific areas of the brain parenchyma (e.g. chorioid plexus), therefore the number of leukaemic cells detected in CSF does not reflect accurately the leukaemic burden of the CNS compartment. Hence, new diagnostic tools are necessary to improve diagnostics.<\/p>\n
Selection of methods applied, technical details of these methods, cut off values, definitions of CSF diagnostics, CNS staging widely vary worldwide, even among nearby hospitals within a given country. Comparison of trial results are therefore based: it is difficult to compare CNS positive cohorts when the diagnostics differ how they were defined as CNS positive. Standardisation of these procedure sare not only important for research purposes, but changes in treatment elements will follow for the patients\u2019 benefit.<\/p>\n
In conclusion, advanced, standardised diagnostic procedures and definitions, plus new, hopefully more sensitive biomarkers could lead to the development of a more accurate treatment stratification of ALL patients, improving clinical outcome and reducing treatment toxicity.<\/p>\n
Virtual biobank:<\/p>\n
Research:<\/p>\n
Unifying, standardising routine CSF diagnostics:<\/p>\n
CNS directed therapy:<\/p>\n
Standard operating protocol for CSF biobanking<\/strong><\/p>\n Due to the rarity of CNS positive cases, it is difficult to implement meaningful research projects on CNS leukaemia locally. Sharing samples across research groups could solve the problem, however sample collecting and storing protocols differ among centres. Therefore, we established an international standard operating protocol (SOP) for the collection, processing, and storage of CSF samples. The main aim is to collect supernatant for soluble biomarker (DNA, RNA, protein, metabolite) research purposes. Additionally, cells (cellular nucleic acids, proteins, etc.) and\/or extracellular vesicles can be stored.<\/p>\n You can download the SOP and useful files for data collection at the bottom of this site.<\/p>\n Childhood ALL CSF Diagnostics Survey<\/strong><\/p>\n A questionnaire has been created to explore how cerebrospinal fluid diagnostics of childhood lymphoblastic leukaemia works in everyday practice. We intend to investigate heterogeneities in clinical practice, laboratory methods and stratification of patient management. The survey has been sent out worldwide to interview a set of selected professionals per country. We hope to publish findings. These will also help to identify critical heterogeneities, towards developing a consensus guidance.<\/p>\n Closed Scientific Mini Symposium, March 2021<\/strong><\/p>\n Among initiative members we have organised a mini symposium, an event where all participants were welcome to show the latest results of their research.<\/p>\n Programme:<\/p>\n 3rd<\/sup> Annual meeting of The European Society for Paediatric Oncology, March 2022<\/strong><\/p>\n The initiative organized a session on CNS leukaemia during the 2022 SIOP-E congress. This was held during the joint session of Biology & Disease, Genetic Variation and ALL I-BFM Committees on 23rd\u00a0March. We introduced our work to a wider audience. The session collated topics on routine CSF diagnostics and CSF biomarker research.<\/p>\n Programme:<\/strong><\/p>\n Join our group and activities if you share our interest!<\/p>\n Contact info:<\/strong><\/p>\n <\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" I-BFM Initiative on CSF ALL Biomarkers is an international collaboration of research groups, working on advancing the research field of paediatric central nervous system (CNS) involvement of acute lymphoblastic leukaemia (ALL). The very first meeting of physicians and researchers interested in the field was initiated by Prof. Christina Halsey in 2018 at the annual I-BFM …<\/p>\n","protected":false},"author":101602,"featured_media":0,"parent":8014,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-8019","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/tuzoltoklinika\/wp-json\/wp\/v2\/pages\/8019","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/tuzoltoklinika\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/semmelweis.hu\/tuzoltoklinika\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/tuzoltoklinika\/wp-json\/wp\/v2\/users\/101602"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/tuzoltoklinika\/wp-json\/wp\/v2\/comments?post=8019"}],"version-history":[{"count":11,"href":"https:\/\/semmelweis.hu\/tuzoltoklinika\/wp-json\/wp\/v2\/pages\/8019\/revisions"}],"predecessor-version":[{"id":8138,"href":"https:\/\/semmelweis.hu\/tuzoltoklinika\/wp-json\/wp\/v2\/pages\/8019\/revisions\/8138"}],"up":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/tuzoltoklinika\/wp-json\/wp\/v2\/pages\/8014"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/tuzoltoklinika\/wp-json\/wp\/v2\/media?parent=8019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/tuzoltoklinika\/wp-json\/wp\/v2\/categories?post=8019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/tuzoltoklinika\/wp-json\/wp\/v2\/tags?post=8019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Events:<\/h4>\n
\n
\n
\n
Files:<\/h4>\n
\n